Venture Capital

RNA biotech Nutcracker Therapeutics unshells $167M for drugs built on biochips


ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for …

Read more

Show More

Related Articles

Back to top button